We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Jemperli plus chemotherapy is the only immuno-oncology-based treatment to show statistically significant and clinically meaningful OS benefit in the overall population
Biocon Biologics remains committed to global standards of quality and compliance
Parents, teachers, and caregivers play a vital role in spotting early signs of schizophrenia
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
With the addition of Karsanbhai, the Merck board will consist of 13 members
Subscribe To Our Newsletter & Stay Updated
